Malignant pleural mesothelioma (MPM) is a rare type of tumor closely associated with asbestos exposure.
Increasing evidence shows that high immuno-heterogeneity reduces the therapeutic efficacy of MPM.
At present, good biomarkers to screen immunodominant populations and predict the efficacy of immunotherapy are lacking.
